Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine.

Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...

Pfizer's legal win invalidates two GSK patents in UK RSV vaccine case. On Monday, Pfizer Inc. PFE stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist ...

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

The company is committing to make at least 2 million doses of its long-acting PrEP therapy available in low- and middle-income countries next year and in 2026.

After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and ...

The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...